|
Miraculins
Inc., a biotechnology company engaged in the discovery and
development of products for select cancers, is pleased to report
positive interim results from the Company's prostate cancer study.
Read More
|
|
Miraculins Inc.,
a biotechnology company engaged in the discovery and development of
products for select cancers, today announces an agreement with the
Winnipeg Clinic, that provides the Company access to additional
clinical samples from prostate cancer patients.
Read More
|
|
Miraculins Inc., a biotechnology company engaged in the
development of products for select cancers, announced today that
investors exercised 100% of the Company's common share purchase
warrants, which expired on September 26, 2004, and were part of
Miraculins' private placement that closed on March 26, 2004.
Read More
|
|
Miraculins
Inc., a biotechnology company engaged in the discovery and
development of products for select cancers, today announces a
collaboration with the Edmonton Prostate and Urological Research
Centre.
Read More
|
|
Miraculins
Inc., a biotechnology company
engaged in the development of products for select cancers, announces
today that the private placement announced on June 29, 2004 of 400,000 units at a price of $1.00 per Unit,
closed today for aggregate gross proceeds to Miraculins Inc. of
$400,000.
Read More
|
|
|